Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Mugglestone

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Lancet (London, England)|September 14, 1985
Dangers of orphenadrine in psychiatric patientsC J Mugglestone
Lancet (London, England)|June 15, 1985
Etidronate and risk of fracturesC J Mugglestone
BMJ (Clinical Research Ed.)|December 2, 1995
Breast cancer and hormonal supplements in postmenopausal women. Increase in risk of breast cancer is smallC J Mugglestone
Clinical and Experimental Dermatology|November 1, 1982
The treatment of acne with an anti-androgen/oestrogen combinationC J Mugglestone, E L Rhodes
British Medical Journal|August 5, 1978
Menopausal therapy and endometrial pathologyI Craft, J Swinhoe, C J Mugglestone
The British Journal of Dermatology|October 1, 1978
A study of the comparative efficacy of diflucortolone valerate 0.3% ointment and clobetasol propionate 0.05% ointmentH Wendt, C J Mugglestone, R A Wiseman
Current Medical Research and Opinion|January 1, 1981
A study of potential skin atrophy following topical application of weak corticosteroidsM M Black, N E Platt, C J Mugglestone
The Journal of International Medical Research|January 1, 1977
Sustained action tetracycline preparation--tetrabid-organon blood level studyC R Lucas, C J Mugglestone, D R Thomas
Acta Obstetricia Et Gynecologica Scandinavica|January 1, 1980
Combined estrogen and progestogen for the menopauseC J Mugglestone, J R Swinhoe, I L Craft
The British Journal of Dermatology|October 1, 1978
Plasma cortisol values after topical application of diflucortolone valerate (0.3%) or clobetasol propionate (0.05%) in psoriatic patientsK Keczkes, P Teasdale, R A Wiseman, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Lancet (London, England)|September 14, 1985
Dangers of orphenadrine in psychiatric patientsC J Mugglestone
Lancet (London, England)|June 15, 1985
Etidronate and risk of fracturesC J Mugglestone
BMJ (Clinical Research Ed.)|December 2, 1995
Breast cancer and hormonal supplements in postmenopausal women. Increase in risk of breast cancer is smallC J Mugglestone
Clinical and Experimental Dermatology|November 1, 1982
The treatment of acne with an anti-androgen/oestrogen combinationC J Mugglestone, E L Rhodes
British Medical Journal|August 5, 1978
Menopausal therapy and endometrial pathologyI Craft, J Swinhoe, C J Mugglestone
The British Journal of Dermatology|October 1, 1978
A study of the comparative efficacy of diflucortolone valerate 0.3% ointment and clobetasol propionate 0.05% ointmentH Wendt, C J Mugglestone, R A Wiseman
Current Medical Research and Opinion|January 1, 1981
A study of potential skin atrophy following topical application of weak corticosteroidsM M Black, N E Platt, C J Mugglestone
The Journal of International Medical Research|January 1, 1977
Sustained action tetracycline preparation--tetrabid-organon blood level studyC R Lucas, C J Mugglestone, D R Thomas
Acta Obstetricia Et Gynecologica Scandinavica|January 1, 1980
Combined estrogen and progestogen for the menopauseC J Mugglestone, J R Swinhoe, I L Craft
The British Journal of Dermatology|October 1, 1978
Plasma cortisol values after topical application of diflucortolone valerate (0.3%) or clobetasol propionate (0.05%) in psoriatic patientsK Keczkes, P Teasdale, R A Wiseman, et al.
Pageof 1